PubMed · 2020 · 53 citations · 23 references
MedicineHealth SciencesInternal MedicineEpidemiologyHepatologyPopulation HealthChronic DiseaseChronic Disease BurdenChronic Liver DiseaseCirrhosisHepatic PathologyLiver DiseaseComplications Of CirrhosisGlobal Burden EstimationLiver Disease Complications
OBJECTIVE: To estimate the burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China. METHODS: Data from the Global Burden of Disease Study 2016 (GBD 2016) were used. We evaluated the burden by analyzing age-sex-province-specific prevalence, mortality, and disability-adjusted life-years (DALYs) of 33 provinces in China. RESULTS: : 11274.6-12504.7). Age-standardized mortality and DALY rates per 100,000 decreased by 51.2% and 53.3%, respectively. Male and elderly people (aged ≥ 60 years) preponderance were found for prevalence, mortality, and DALYs. The number of prevalence cases, deaths, and DALYs due to hepatitis C virus (HCV) increased by 86.6%, 8.7%, and 0.9%, respectively. Also, age-standardized prevalence rates decreased in 31 provinces, but increased in Yunnan and Shandong. The Socio-demographic Index (SDI) values were negatively correlated with age-standardized mortality and DALY rates by provinces in 2016; the correlation coefficients were -0.817 and -0.828, respectively. CONCLUSION: Cirrhosis and other chronic liver diseases remain a huge health burden in China, with the increase of population and the aging of population. Hepatitis B virus (HBV) remains the leading cause of the health burden in China.
23
Rafael Lozano, Mohsen Naghavi, Kyle J Foreman et al. · The Lancet · 2012 · 14.3K citations · Full text
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate et al. · The Lancet · 2017 · 13.5K citations · Full text
Christopher J L Murray, Theo Vos, Rafael Lozano et al. · The Lancet · 2012 · 9K citations
Mohsen Naghavi, Amanuel Alemu Abajobir, Cristiana Abbafati et al. · The Lancet · 2017 · 4.9K citations · Full text
The Lancet · 2018 · 4.2K citations · Full text